ArticleBDJ open2025
Intratumoral microbiota drive immune evasion and disease progression in oral squamous cell carcinoma.
Article in BDJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveEmerging evidence suggests that oral squamous cell carcinoma (OSCC) harbors distinct microbial communities, yet their influence on tumor immunobiology remains unclear. This study investigated the prognostic value of intratumoral microbiota and their role in modulating CD8⁺ T-cell function. MATERIALS AND
methodsUsing TCGA datasets, a 19-microorganism prognostic signature was constructed via Cox and LASSO regression and validated with Kaplan-Meier survival analysis. Comprehensive bioinformatics analyses, including GSEA/GSVA, CIBERSORT, ESTIMATE, pharmacogenomics, and mutational profiling, were performed to explore underlying mechanisms.
resultsThe microbial signature demonstrated strong predictive performance, with higher risk scores significantly associated with reduced overall survival (p < 0.001). High-risk tumors exhibited enrichment of PI3K/AKT/mTOR signaling, metabolic reprogramming, and epithelial-mesenchymal transition, alongside an immunosuppressive microenvironment characterized by CD8⁺ T-cell depletion, M0 macrophage infiltration, and upregulation of immunosuppressive markers including CD276 and TGF-β1. Conversely, immune-activating checkpoints such as PD-1 and CTLA-4 were elevated in low-risk tumors. Notably, periodontal pathogens negatively correlated with immune effector activity, and TP53 mutations were more frequent in high-risk cases (82% vs. 67%).
conclusionsThis study identified intratumoral microbial signatures as independent prognostic biomarkers and validated their reproducibility in an external cohort. Our findings support a microbiota-immune axis contributing to immune evasion in OSCC, offering novel avenues for prognostic stratification and therapeutic intervention.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.